-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Every April 20th is the "World Gout Day".
According to data, the prevalence of hyperuricemia in China has reached 13.
3%, and the number of patients has reached 180 million.
Nearly 100 million people suffer from gout.
The new pain point of contemporary people
.
At present, the treatment of gout is mainly based on chemical drugs.
In December 2021, the first class 1 new drug of traditional Chinese medicine for the treatment of gout in China, Huzhen Qingfeng Capsule, was approved for marketing, setting off a new heat wave of traditional Chinese medicine for the treatment of gout
.
Figure 1: Market size of chemical anti-gout preparations in recent years (unit: 100 million yuan) Source: Minet.
com China's public medical institutions terminal competition The market size of the terminal chemical drug anti-gout preparations in the center and township health centers (referred to as Chinese public medical institutions) is more than 2 billion yuan, and the growth rate in the first half of 2021 has dropped by 47.
82%
.
Figure 2: The winning bids for febuxostat in China Source: The TOP1 variety of febuxostat in the new version of Minet.
com’s database is a large variety of over 1 billion.
After being included in the third batch of domestic harvests, the price dropped sharply.
Market share slipped to 46.
12%
.
Under the impact of centralized procurement, the anti-gout drug market is showing a sluggish trend
.
In recent years, the launch of Category 1 Chinese patent medicines has accelerated.
In 2021, a total of 7 new drugs have been approved, of which 2 are for musculoskeletal diseases.
And Yili Pharmaceutical's Huzhen Qingfeng Capsule is used to treat mild to moderate acute gouty arthritis
.
Table 1: Recently approved clinical anti-gout TCM class 1 new drugs Source: CDE official website Huzhen Qingfeng Capsule has become the first class 1 new TCM drug approved for the treatment of gout in China.
Class 1 new drugs of traditional Chinese medicine for the treatment of hyperuricemia and gout have been approved for clinical use
.
Source: Minet database, CDE official website
According to data, the prevalence of hyperuricemia in China has reached 13.
3%, and the number of patients has reached 180 million.
Nearly 100 million people suffer from gout.
The new pain point of contemporary people
.
At present, the treatment of gout is mainly based on chemical drugs.
In December 2021, the first class 1 new drug of traditional Chinese medicine for the treatment of gout in China, Huzhen Qingfeng Capsule, was approved for marketing, setting off a new heat wave of traditional Chinese medicine for the treatment of gout
.
Figure 1: Market size of chemical anti-gout preparations in recent years (unit: 100 million yuan) Source: Minet.
com China's public medical institutions terminal competition The market size of the terminal chemical drug anti-gout preparations in the center and township health centers (referred to as Chinese public medical institutions) is more than 2 billion yuan, and the growth rate in the first half of 2021 has dropped by 47.
82%
.
Figure 2: The winning bids for febuxostat in China Source: The TOP1 variety of febuxostat in the new version of Minet.
com’s database is a large variety of over 1 billion.
After being included in the third batch of domestic harvests, the price dropped sharply.
Market share slipped to 46.
12%
.
Under the impact of centralized procurement, the anti-gout drug market is showing a sluggish trend
.
In recent years, the launch of Category 1 Chinese patent medicines has accelerated.
In 2021, a total of 7 new drugs have been approved, of which 2 are for musculoskeletal diseases.
And Yili Pharmaceutical's Huzhen Qingfeng Capsule is used to treat mild to moderate acute gouty arthritis
.
Table 1: Recently approved clinical anti-gout TCM class 1 new drugs Source: CDE official website Huzhen Qingfeng Capsule has become the first class 1 new TCM drug approved for the treatment of gout in China.
Class 1 new drugs of traditional Chinese medicine for the treatment of hyperuricemia and gout have been approved for clinical use
.
Source: Minet database, CDE official website
